JP6750140B2 - 直腸結腸がんを早期検出するための方法 - Google Patents

直腸結腸がんを早期検出するための方法 Download PDF

Info

Publication number
JP6750140B2
JP6750140B2 JP2017529971A JP2017529971A JP6750140B2 JP 6750140 B2 JP6750140 B2 JP 6750140B2 JP 2017529971 A JP2017529971 A JP 2017529971A JP 2017529971 A JP2017529971 A JP 2017529971A JP 6750140 B2 JP6750140 B2 JP 6750140B2
Authority
JP
Japan
Prior art keywords
crp
cyfra
cea
subject
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2017529971A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017532577A (ja
JP2017532577A5 (enExample
Inventor
デイビス，ジェラード・ジェイ
ガウェル，スーザン・エイチ
ヤン，シャオチン
ニルスン，ハンス・ヨーエン
クリステンセン，イブ・ヤーレ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Laboratories
Original Assignee
Abbott Laboratories
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Laboratories filed Critical Abbott Laboratories
Publication of JP2017532577A publication Critical patent/JP2017532577A/ja
Publication of JP2017532577A5 publication Critical patent/JP2017532577A5/ja
Application granted granted Critical
Publication of JP6750140B2 publication Critical patent/JP6750140B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G01N33/57535—
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57419—Specifically defined cancers of colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4737—C-reactive protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4742—Keratin; Cytokeratin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Microbiology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017529971A 2014-08-22 2015-08-21 直腸結腸がんを早期検出するための方法 Expired - Fee Related JP6750140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462040874P 2014-08-22 2014-08-22
US62/040,874 2014-08-22
PCT/US2015/046301 WO2016029117A1 (en) 2014-08-22 2015-08-21 Methods for the early detection of colorectal cancer

Publications (3)

Publication Number Publication Date
JP2017532577A JP2017532577A (ja) 2017-11-02
JP2017532577A5 JP2017532577A5 (enExample) 2018-10-04
JP6750140B2 true JP6750140B2 (ja) 2020-09-02

Family

ID=54035324

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017529971A Expired - Fee Related JP6750140B2 (ja) 2014-08-22 2015-08-21 直腸結腸がんを早期検出するための方法

Country Status (6)

Country Link
US (1) US20160178631A1 (enExample)
EP (1) EP3183578B8 (enExample)
JP (1) JP6750140B2 (enExample)
CN (1) CN107110865B (enExample)
ES (1) ES2813829T3 (enExample)
WO (1) WO2016029117A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3096391A1 (en) * 2018-04-12 2019-10-17 Board Of Regents, The University Of Texas System Biomarker for detecting cancer
WO2020091408A1 (ko) * 2018-10-30 2020-05-07 주식회사 애니벳 반려동물에서 종양질병의 보조적 진단을 위한 바이오마커 검사방법
KR102407703B1 (ko) * 2018-10-30 2022-06-22 바디텍메드(주) 반려동물의 종양 질병을 보조적으로 진단하는 바이오마커 검사방법
CN109557311B (zh) * 2018-12-13 2022-02-15 中南大学湘雅医院 结直肠癌诊断标志物及结直肠癌的检测产品及其应用
WO2021024009A1 (en) * 2019-08-02 2021-02-11 Shanghai Yunxiang Medical Technology Co., Ltd. Methods and compositions for providing colon cancer assessment using protein biomarkers
US20240019440A1 (en) * 2019-10-18 2024-01-18 Exact Sciences Corporation Multiple analyte fecal antigen testing
CN113018416B (zh) * 2021-03-09 2022-09-20 复旦大学附属中山医院 天冬酰胺内肽酶抑制剂的制药用途
CN118197643B (zh) * 2024-04-03 2025-01-07 南通大学附属医院 基于肠道环境数据的肠道肿瘤检测系统

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060154245A1 (en) * 1999-04-09 2006-07-13 Rigshospitalet Method for detecting, screening and/or montoring a cancer in individual
US20040157278A1 (en) * 2002-12-13 2004-08-12 Bayer Corporation Detection methods using TIMP 1
WO2005124355A1 (en) * 2004-06-18 2005-12-29 Roche Diagnostics Gmbh Use of protein rs15a as a marker for colorectal cancer
BRPI0419002A (pt) * 2004-08-13 2007-12-11 Indivumed Gmbh método para detectar e para diferenciação entre adenoma colorretal e/ou carcinoma colorretal, método para monitoramento do curso de adenoma colorretal, uso de transtirretina como biomarcador, sistema de teste, arranjo compreendendo moléculas de detecção
ES2325277T3 (es) * 2004-12-23 2009-08-31 F. Hoffmann-La Roche Ag Uso de cyfra 21-1 y osteopontina, como marcadores para el cancer colorrectal.
CN101238373A (zh) * 2005-08-19 2008-08-06 因迪维姆德有限公司 内质蛋白片段及其衍生物作为结肠直肠腺瘤和/或癌的生物标记的用途；用于检测的方法和测试系统
JP2009520958A (ja) * 2005-12-22 2009-05-28 エフ．ホフマン−ラ ロシュ アーゲー 結腸直腸癌の評価におけるオステオポンチンおよび癌胎児性抗原を含むマーカー組合せの使用
EP2223116B1 (en) * 2007-12-10 2014-11-19 Roche Diagnostics GmbH Marker panel for colorectal cancer
EP2071337A1 (en) * 2007-12-10 2009-06-17 F.Hoffmann-La Roche Ag Seprase as a marker for cancer
ES2439966T3 (es) * 2008-11-12 2014-01-27 F. Hoffmann-La Roche Ag PACAP como marcador para el cáncer
US10815517B2 (en) * 2009-04-28 2020-10-27 Roche Diagnostics Operations, Inc. Use of DPPIV/seprase as a marker for cancer
EP2427772B1 (en) * 2009-05-04 2015-01-21 Roche Diagnostics GmbH Use of dppiv/seprase as a marker for cancer
EP2556172A4 (en) * 2010-04-06 2013-10-30 Caris Life Sciences Luxembourg Holdings CIRCULATING BIOMARKERS FOR DISEASES
CN103080334B (zh) * 2010-06-04 2016-05-04 复旦大学 用于诊断早期结直肠癌及高级腺瘤的微rna生物标记及方法
US20130090258A1 (en) * 2010-06-16 2013-04-11 National University Corporation Hamamatsu University School Of Medicines Method for detecting colorectal tumor
CN103492590A (zh) * 2011-02-22 2014-01-01 卡里斯生命科学卢森堡控股有限责任公司 循环生物标志物
JP5805518B2 (ja) * 2011-12-21 2015-11-04 株式会社島津製作所 マルチプレックス大腸がんマーカーパネル
KR101461615B1 (ko) * 2012-01-03 2015-04-22 국립암센터 암 진단 장치

Also Published As

Publication number Publication date
CN107110865A (zh) 2017-08-29
CN107110865B (zh) 2020-01-10
EP3183578A1 (en) 2017-06-28
US20160178631A1 (en) 2016-06-23
ES2813829T3 (es) 2021-03-25
EP3183578B8 (en) 2020-07-15
JP2017532577A (ja) 2017-11-02
EP3183578B1 (en) 2020-06-03
WO2016029117A1 (en) 2016-02-25

Similar Documents

Publication Publication Date Title
JP6750140B2 (ja) 直腸結腸がんを早期検出するための方法
Yie et al. Detection of survivin-expressing circulating cancer cells (CCCs) in peripheral blood of patients with gastric and colorectal cancer reveals high risks of relapse
US20140271621A1 (en) Methods of prognosis and diagnosis of pancreatic cancer
US20140271453A1 (en) Methods for the early detection of lung cancer
Gude et al. Colorectal cancer diagnostic methods: the present and future
JP2021060418A (ja) 肝細胞癌および膵臓がんを診断するためのラミニン２の使用
CN113718031A (zh) 一种卵巢癌早期诊断组合物的建立
US20240279741A1 (en) KIT FOR DIAGNOSING GASTRIC CANCER USING miRNA EXPRESSION
CN101539574A (zh) Survivin抗体的应用及以其制备的食管癌免疫层析检测试纸条
Kim et al. Stage and mRNA expression of survivin in lymph node as prognostic indicators in patients with oral squamous cell carcinoma
CA3062706A1 (en) Methods for diagnosing high-risk cancer using polysialic acid and one or more tissue-specific biomarkers
Soufi et al. Primary gastric leiomyosarcoma in young revealed by a massive hematemesis
TW201226903A (en) Methods and compositions for detection of lethal system and uses thereof
CN115372616B (zh) 胃癌相关的生物标志物及其应用
US20090123487A1 (en) Precursors and enzymes associated with post translational modification of proteins implicated in isoform generation of PCNA
CN114286942B (zh) 检测癌症的方法
CN116262941A (zh) Fam227a作为肿瘤生物标志物的用途
US20240058334A1 (en) Methods for treating small cell lung cancer and other neuroendocrine cancers
Fietsch Follow-Up of superficial urothelial carcinoma with non-invasive diagnostic tools. literature review
CN102735831A (zh) 截短型维甲酸诱导蛋白tRAI16用作肝细胞癌标志物的应用
CN108318688A (zh) 外周血外泌体中Smad3蛋白作为分子标记的应用、肝癌检测试剂盒
Zhen et al. Clinical significance of plasma free DNA concentration and integrity in detection of primary hepatocellular carcinoma
CN121057942A (zh) 使用H3K27Me3和ctDNA作为标志物的NSCLC的检测方法
RU2319148C1 (ru) Способ оценки распространенности заболевания у больных неходжкинскими лимфомами
WO2024226573A2 (en) Masp-2 directed cancer treatment methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180821

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180821

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190523

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190709

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191004

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20200212

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200311

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20200312

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200311

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200707

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200707

R150 Certificate of patent or registration of utility model

Ref document number: 6750140

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees